Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses

Overview of attention for article published in BMC Cancer, July 2020

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 9 publications that cite this research output.

9

The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab

Article in Scientific Reports (February 2023)

Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study

Article in BMC Cancer (January 2022)

Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later‐line nivolumab monotherapy—The Asahikawa Gastric Cancer Cohort Study (AGCC)

Article in Cancer Medicine (November 2021)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.